The FDA is moving faster on psychedelics — now Washington must do more
The FDA is expediting the review of psychedelic medicines to address the mental health crisis in the U.S. Millions of Americans struggle with mental health issues, and traditional treatments often fall short. The approval process for these treatments must be swift to provide relief to those in need.
- ▪Every 11 minutes, an American dies by suicide, highlighting the urgency of addressing mental health issues.
- ▪The FDA has announced plans to fast-track the review of psychedelic medicines in response to a presidential executive order.
- ▪More than 120 clinical trials involving psilocybin compounds are currently underway, showing promising results for treating depression.
Opening excerpt (first ~120 words) tap to expand
Every 11 minutes, an American dies by suicide. Millions more struggle to manage their mental health, cycling through medications, therapy appointments, and hospital visits without ever finding relief. In late April, the FDA took a decisive step toward addressing this prolonged health emergency. In response to President Donald Trump’s recent executive order, the agency announced plans to expedite the review of certain psychedelic medicines for serious mental health conditions. Recommended Stories Rural America is consequential in the congressional midterm elections Retirement nest eggs are in jeopardy. SAFER Act is the answer Trump’s Iran conflict: The first geo-economic war of the 21st century It’s about time.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
